Travere Therapeutics shared projections of approximately $127 million in total U.S. net product sales for Q4 2025 and expects to close fiscal year 2025 with around $410 million in sales, indicating robust revenue growth.
Ending 2025 with approximately $323 million in cash and marketable securities empowers Travere Therapeutics to fund future growth and innovation initiatives.
The company outlined pivotal corporate, clinical, and regulatory endeavors for 2026, highlighting the upcoming commercial launch of FILSPARI in FSGS and the resumption of the HARMONY study in classical HCU.
Record Sales Performance
Preliminary U.S. net product sales of FILSPARI in Q4 2025 soared to around $103 million, marking a remarkable 108% year-over-year growth, showcasing the strong market acceptance of the product.
FILSPARI Expansion
With 908 new patient start forms received during the quarter, demand for FILSPARI remains robust, signaling sustained interest and utilization of the medication in the market.
Future Milestones
Travere Therapeutics outlined significant goals for 2026, including further clinical validation of FILSPARI's efficacy in IgAN and the planned submission of a New Drug Application in Japan for sparsentan, indicating strategic geographic expansion.
- The exceptional performance in Q4 2025 underscores Travere Therapeutics' effective commercial strategy, positioning the company for continued revenue growth and market penetration.
- The forthcoming milestones in 2026 signal a commitment to innovation and strategic expansion in key therapeutic segments, enhancing the company's competitive positioning and long-term growth prospects.
Travere Therapeutics is strategically positioned for a prosperous 2026, leveraging strong sales performance, robust cash reserves, and a pipeline of upcoming milestones to drive growth and development within the pharmaceutical industry, reinforcing investor confidence in the company's future outlook.